| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
| 07/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/27/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 07/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/07/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/12/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/01/2023 |
SC 13G
| INTRACOASTAL CAPITAL, LLC reports a 5% stake in Dermata Therapeutics, Inc. |
| 05/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
SC 13D/A
| HALE DAVID F reports a 1.9% stake in Dermata Therapeutics, Inc. |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/20/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 03/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/16/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/13/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/13/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 03/01/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 02/08/2023 |
8-K
| Quarterly results |
| 01/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 01/05/2023 |
4
| Bedoya-Toro Munera Maria E (SVP, Regulatory Affairs) has filed a Form 4 on Dermata Therapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $0.31, valued at
$15.5k
|
|
| 01/05/2023 |
4
| Van Hoose Kyri K. (SVP, CFO) has filed a Form 4 on Dermata Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.31, valued at
$31k
|
|
| 01/05/2023 |
4
| Nardo Christopher J. (Senior VP, CDO) has filed a Form 4 on Dermata Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.31, valued at
$31k
|
|
| 01/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 12/29/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 12/15/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 12/05/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/28/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|